Skip to main content Skip to office menu Skip to footer
Minnesota Legislature

House MN

Health and Human Services Finance Division - Meeting Minutes

2019-2020 Regular Session
TWENTY-SEVENTH MEETING - 3/14/2019
TWENTY-SIXTH MEETING - 3/13/2019
TWENTY-FIFTH MEETING - 3/12/2019
TWENTY-FOURTH MEETING - 3/7/2019
TWENTY-THIRD MEETING - 3/6/2019
TWENTY-SECOND MEETING - 3/5/2019
TWENTY-FIRST MEETING - 2/28/2019
TWENTIETH MEETING - 2/27/2019
NINETEENTH MEETING - 2/26/2019
EIGHTEENTH MEETING - 2/21/2019
SEVENTEENTH MEETING - 2/20/2019
SIXTEENTH MEETING - 2/19/2019
FIFTEENTH MEETING - 2/14/2019
FOURTEENTH MEETING - 2/13/2019
THIRTEENTH MEETING - 2/12/2019
TWELFTH MEETING - 2/7/2019
ELEVENTH MEETING - 2/6/2019
TENTH MEETING - 2/5/2019
NINTH MEETING - 1/31/2019
EIGHTH MEETING - 1/30/2019
SEVENTH MEETING - 1/29/2019
SIXTH MEETING - 1/24/2019
FIFTH MEETING - 1/23/2019
FOURTH MEETING - 1/22/2019
THIRD MEETING - 1/17/2019
SECOND MEETING - 1/16/2019
FIRST MEETING - 1/15/2019

Upcoming Meetings..

Thursday, April 04, 2019 at 12:45 PM

Chair: Rep. Tina Liebling
Location: 200 State Office Building
Agenda:

TBD

Wednesday, April 03, 2019 at 12:45 PM

Chair: Rep. Tina Liebling
Location: 200 State Office Building
Agenda:

TBD

Tuesday, April 02, 2019 at 12:45 PM

Chair: Rep. Tina Liebling
Location: 200 State Office Building
Agenda:

TBD

Monday, April 01, 2019 at 12:00 PM

Chair: Rep. Tina Liebling
Location: 200 State Office Building
Agenda:

TBD

Friday, March 29, 2019 at 9:00 AM

Chair: Rep. Tina Liebling
Location: 200 State Office Building
Agenda:

TBD

Thursday, March 28, 2019 at 12:45 PM

Chair: Rep. Tina Liebling
Location: 200 State Office Building
Agenda:

TBD

Wednesday, March 27, 2019 at 12:45 PM

Chair: Rep. Tina Liebling
Location: 200 State Office Building
Agenda:

TBD

Tuesday, March 26, 2019 at 12:45 PM

Chair: Rep. Tina Liebling
Location: 200 State Office Building
Agenda:

HF728 (Mann) Pharmacy benefit managers licensure and regulations created, and rulemaking authorized. HF4 (Lesch) Drug manufacturer or wholesale distributor prohibited from charging unconscionable prices for prescription drugs; Board of Pharmacy, commissioner of human services, and health plan companies required to notify the attorney general of certain prescription drug price increases; attorney general authorized to take action against drug manufacturers and wholesalers related to price increases; and civil penalties imposed. HF485 (Howard) Pharmaceutical assistance program established, insulin assistance account in the special revenue fund established, fees and penalties established, and money appropriated. HF1246 (Morrison) Prescription Drug Price Transparency Act established, and report required. HF1523 (Cantrell) Commissioner of human services directed to establish prescription drug purchasing program, and program authority and eligibility requirements specified. HF1257 (Cantrell) Prescription drug benefit transparency and disclosure required. HF687 (Bahner) Prescription drug coverage and refills sections modified. HF815 (Acomb) Step therapy override procedures applied to state public health care programs. HF2009 (Cantrell) Health plan companies and commissioner of human services prohibited from requiring enrollees to follow metastatic cancer step therapy protocols. Bills may be added or removed.

Bills:
  • HF728 (Mann) - Pharmacy benefit managers licensure and regulations created, and rulemaking authorized.
  • HF4 (Lesch) - Drug manufacturer or wholesale distributor prohibited from charging unconscionable prices for prescription drugs; Board of Pharmacy, commissioner of human services, and health plan companies required to notify the attorney general of certain prescription drug price increases; attorney general authorized to take action against drug manufacturers and wholesalers related to price increases; and civil penalties imposed.
  • HF485 (Howard) - Pharmaceutical assistance program established, insulin assistance account in the special revenue fund established, fees and penalties established, and money appropriated.
  • HF1246 (Morrison) - Prescription Drug Price Transparency Act established, and report required.
  • HF1523 (Cantrell) - Commissioner of human services directed to establish prescription drug purchasing program, and program authority and eligibility requirements specified.
  • HF1257 (Cantrell) - Prescription drug benefit transparency and disclosure required.
  • HF687 (Bahner) - Prescription drug coverage and refills sections modified.
  • HF815 (Acomb) - Step therapy override procedures applied to state public health care programs.
  • HF2009 (Cantrell) - Health plan companies and commissioner of human services prohibited from requiring enrollees to follow metastatic cancer step therapy protocols.